Drug Discovery

PRI focuses on in vitro and in vivo models of disease across multiple therapeutic areas:

Hematology/Oncology

  • Angiogenesis modulation
  • Thrombosis (Coagulation/platelet)
  • Cancer biology

Cardiovascular (Dyslipidemia)

  •  LDL-C lowering targets
  • HDL-C raising targets
  • Preclinical models of dyslipidemia
  • Targeted delivery

Vascular Diseases

  • Peripheral Artery Disease
    • Cell therapy
    • Pharmacotherapy
    • Combination therapy
  • Cardiovascular Diseases
    • Acute Coronary Syndrome
  • Cerebrovascular Diseases
    • Stroke

Ophthalmology

  • Downregulation of pathological angiogenesis (retina and choroidal neovascularization) in diabetic retinopathy and macular degeneration
  • Ocular delivery of angiogenesis modulators

Neurology

  • Pain modulation in cancer, inflammatory, and other disorders
  • Nano-targeted delivery across the blood-brain barrier

Inflammation

  • Development of novel anti-inflammatory targets including NFκB and other pathways in various acute and chronic inflammatory disorders